Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: A systematic review and meta-analysis

Obesity Reviews

Volumn 9, Issue 5, 2008, Pages 420-427

  Neovius, M ^a,b   Johansson, K ^a   Rossner S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Obesity; Orlistat; Pharmaco therapy; Sibutramine

Indexed keywords

METFORMIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG APPROVAL; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; OBESITY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CYCLOBUTANES; FEMALE; HUMANS; LACTONES; MALE; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 49649101096     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2008.00463.x     Document Type: Review

References (23)

1. Bray GA. Contemporary Diagnosis and Management of Obesity, 2nd edn. Handbooks in Health Care Co Newtown, PA, 2003.
2. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004 CD004094.
3. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006 CD006162.
4. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess (Winchester, England) 2004 8:iii iv, 1 182.
5. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant). Advisory Committee - June 13, 2007. {WWW document}. URL http://www.fda.gov/ohrms/dockets/ ac/07/briefing/2007-4306b1-fda-backgrounder.pdf (accessed September 2007).
6. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007 370:1706 1713.
7. Rucker D, Padwal R, Li S, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007 335:1194 1199.
8. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999 354:1896 1900.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7:177 188.
10. Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dagar A. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004 202:173 180.
11. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 2004 17:222 229.
12. Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005 7:47 55.
13. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, Basci I, Tutuncu N, Guvener N. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002 4:49 55.
14. Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. Eat Weight Disord 2006 11:e127 32.
15. Kaya A, Aydin N, Topsever P, Filiz M, Ozturk A, Dagar A, Kilinc E, Ekmekcioglu C. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004 58:582 587.
16. Rodrigues AM, Radominski RB, Suplicy Hde L, De Almeida SM, Niclewicz PA, Boguszewski CL. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J Clin Endocrinol Metab 2002 87:1621 1626.
17. Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004 30:159 167.
18. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000 8:431 437.
19. Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 42:1011 1019.
20. Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N. Open-label study for the comparison of metabolic effects of orlistat and sibutramine in women participating in an Obesity management program. Turk Jem 2007 11:54 58.
21. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003 326:472.
22. National Institute for Health and Clinical Excellence. CG43 obesity: full guideline, section 1 - introduction, methods and recommendations, 2006. {WWW document}. URL http://guidance.nice.org.uk/CG43/guidnace/section1/word/English (cited November 2007).
23. FASS. {WWW document}. URL http://www.FASS.se (cited November 2007).